Neoadjuvant almonertinib followed by chemo-immunotherapy in II-IIIb EGFR-mutant NSCLC: A single arm, phase II study (NEOVADE).

AiRuiLi (adebrelimab) - Jiangsu Hengrui Pharma

Ameile (aumolertinib) - Jiangsu Hansoh Pharma

https://www.asco.org/abstracts-presentations/267928

Jun-Tao Lin; Zi-Yi Xu; Jia-Tao Zhang; Jie Yang; Sheng Zhang; Jing-Yu Hou; Rui Fu; Zi-Hao Chen; Zhen-Bin Qiu; Yi-Long Wu; Wenzhao Zhong; Chao Zhang; Lixu Yan; Xuening Yang; Song Dong; Ben-Yuan Jiang; Qiang Nie; Ri-qiang Liao; Jing Kang

Apr 21, 2026